Market Pulse
Europe open: Stocks push higher as Deutsche Bank recovers
European stocks rose in early trade as Deutsche Bank recovered from recent losses.
Anglo American sees solid De Beers rough diamond demand
Anglo American said sales at its De Beers diamond business were not as quiet as expected in the eighth sales cycle of the year.
London open: Stocks rise as weaker sterling boosts FTSE
Stocks in London rose in early trade as the weaker pound benefited exporters in the FTSE 100.
Derwent lets east London property at £52 per square foot
FTSE 250 property investor Derwent London reported that it had let part of its east London property to a Cabinet Office service, in order for it to be nearer to city’s technology hub.
Carillion wins £350m Nationwide facilities management contract renewal
Outsourcing company Carillion won a seven-year contract extension from Nationwide Building Society worth around £350m to provide facility management services at its branches and offices.
Astrazeneca wins Nice and beta-blocker deals but loses in Brilinta trial
It was two out of three for Astrazeneca on Tuesday as disappointment over the unsuccessful conclusion of a huge drug trial was offset by a win with the NHS drug regulator for one of its big cancer drugs and a licence deal for a beta-blocker medicine.
Greggs sales rise with healthier summer options
Bakery retail chain Greggs posted its third quarter trading update on Tuesday morning, with total sales up 5. 6% for the 13 weeks to 1 October and like-for-like sales up 3. 4%.
Wizz Air passenger numbers and load factor rise in September
Central and Eastern Europe-focused low-cost airline Wizz Air reported a rise in passenger numbers and load factor in September.
London pre-open: Stocks seen slightly weaker; construction PMI eyed
Stocks in London were set for a slightly weaker open on Tuesday following a positive close in the previous session, as the pound continues to struggle.
Tuesday newspaper round-up: AstraZeneca, rental housing, BT, BP
AstraZeneca has won a major victory in the UK after the country's drugs watchdog approved one of the most important cancer drugs in its oncology portfolio. The National Institute for Health and Care Excellent (Nice) announced on Tuesday that osimertinib, known under the brand name Tagrisso, will be made available to people with a certain type of lung cancer through the Cancer Drugs Fund (CDF). - Telegraph.